Safety and Efficacy of Longan and Lingzhi Mushroom Syrup on Immune and Inflammatory Responses in Healthy Volunteers
- Conditions
- Safety Issues
- Interventions
- Dietary Supplement: Longan and lingzhi mushroom syrup
- Registration Number
- NCT04728009
- Lead Sponsor
- Chulalongkorn University
- Brief Summary
This study aimed to preliminarily determine safety and efficacy of longan and lingzhi mushroom syrup on immune and inflammatory responses. Apparently healthy Thai adults (N = 8) aged 18-60 years were recruited into a prospective, single-group study. All participants were assigned to consume 5 mL of longan and lingzhi mushroom syrup daily for 12 weeks. Blood concentrations of fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), BUN (blood urea nitrogen), creatinine (Cr), immunoglobulins (IgG, IgM, IgA, and IgE), and C-reactive protein (CRP) were measured at baseline (week 0), week 4, week 8, and week 12.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
- Apparently healthy adults at Mae Fah Luang University and Chulalongkorn University
- aged 18-60 years
- HbA1c < 7%
- self-reported immunodeficiency diseases, autoimmune diseases, infectious diseases, diabetes, thyroid diseases, cancer, hepatic- and/or renal dysfunction, uncontrollable illnesses and life-threatening diseases
- being allergic to longan and lingzhi products
- taking medications, herbs, and diet supplements affecting immune system, inflammatory response, and blood glucose a month before study enrollment
- pregnant and breastfeeding women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description longan and lingzhi mushroom syrup Longan and lingzhi mushroom syrup All participants (N = 8) were asked to consume 5 mL of longan and lingzhi mushroom syrup as a sweetener daily for 12 weeks.
- Primary Outcome Measures
Name Time Method Adverse effects on long-term glycemic control 12 weeks Blood concentrations of HbA1C (in %) were measured.
Adverse effects on renal function (1) 12 weeks Blood concentrations of blood urea nitrogen (in mg/dL) were measured.
Adverse effects on fasting blood glucose 12 weeks Blood concentrations of fasting blood glucose (in mg/dL) were measured.
Adverse effects on hepatic function (1) 12 weeks Blood concentrations of aspatate aminotransferase (AST) (in units/L) were measured.
Adverse effects on hepatic function (3) 12 weeks Blood concentrations of alkaline phosphatase (ALP) (in units/L) were measured.
Adverse effects on hepatic function (2) 12 weeks Blood concentrations of alanine aminotransferase (ALT) (in units/L) were measured.
Adverse effects on renal function (2) 12 weeks Blood concentrations of serum creatinine (in mg/dL) were measured.
- Secondary Outcome Measures
Name Time Method Effect on immune responses (3) 12 weeks Blood concentrations of Ig A (in mg/dL) were measured.
Effect on immune responses (1) 12 weeks Blood concentrations of immunoglobulin (Ig) G (in mg/dL) were measured.
Effect on immune responses (2) 12 weeks Blood concentrations of Ig M (in mg/dL) were measured.
Effect on immune responses (4) 12 weeks Blood concentrations of Ig E (in IU/mL) were measured.
Effect on inflammatory responses 12 weeks Blood concentrations of C-reactive protein (in mg/L) were measured.
Trial Locations
- Locations (1)
Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn Unviersity
🇹ðŸ‡Bangkok, Thailand